World Library  
My Account |  Register |  Help  
  
Flag as Inappropriate
Email this Article

Cdkn2c

Article Id: WHEBN0014763775
Reproduction Date:

Title: Cdkn2c  
Author: World Heritage Encyclopedia
Language: English
Subject: Postreplication checkpoint, Cellular apoptosis susceptibility protein, Cyclin B2, CDKN2D, Cyclin-dependent kinase 10
Collection:
Publisher: World Heritage Encyclopedia
Publication
Date:
 

Cdkn2c

Cyclin-dependent kinase inhibitor 2C (p18, inhibits CDK4)

PDB rendering based on 1bu9.
Available structures
PDB Ortholog search: PDBe, RCSB
Identifiers
Symbols  ; INK4C; p18; p18-INK4C
External IDs GeneCards:
RNA expression pattern
Orthologs
Species Human Mouse
Entrez
Ensembl
UniProt
RefSeq (mRNA)
RefSeq (protein)
Location (UCSC)
PubMed search

Cyclin-dependent kinase 4 inhibitor C is an enzyme that in humans is encoded by the CDKN2C gene.[1][2][3] The protein encoded by this gene is a member of the INK4 family of cyclin-dependent kinase inhibitors. This protein has been shown to interact with CDK4 or CDK6, and prevent the activation of the CDK kinases, thus function as a cell growth regulator that controls cell cycle G1 progression. Ectopic expression of this gene was shown to suppress the growth of human cells in a manner that appears to correlate with the presence of a wild-type RB1 function. Studies in the knockout mice suggested the roles of this gene in regulating spermatogenesis, as well as in suppressing tumorigenesis. Two alternatively spliced transcript variants of this gene, which encode an identical protein, have been reported.[3]

Contents

  • Interactions 1
  • References 2
  • Further reading 3
  • External links 4

Interactions

CDKN2C has been shown to interact with Cyclin-dependent kinase 4[1][4] and Cyclin-dependent kinase 6.[1][4][5]

References

  1. ^ a b c Guan KL, Jenkins CW, Li Y, Nichols MA, Wu X, O'Keefe CL, Matera AG, Xiong Y (January 1995). "Growth suppression by p18, a p16INK4/MTS1- and p14INK4B/MTS2-related CDK6 inhibitor, correlates with wild-type pRb function". Genes Dev 8 (24): 2939–52.  
  2. ^ Blais A, Labrie Y, Pouliot F, Lachance Y, Labrie C (July 1998). "Structure of the gene encoding the human cyclin-dependent kinase inhibitor p18 and mutational analysis in breast cancer". Biochem Biophys Res Commun 247 (1): 146–53.  
  3. ^ a b "Entrez Gene: CDKN2C cyclin-dependent kinase inhibitor 2C (p18, inhibits CDK4)". 
  4. ^ a b Ewing, Rob M; Chu Peter, Elisma Fred, Li Hongyan, Taylor Paul, Climie Shane, McBroom-Cerajewski Linda, Robinson Mark D, O'Connor Liam, Li Michael, Taylor Rod, Dharsee Moyez, Ho Yuen, Heilbut Adrian, Moore Lynda, Zhang Shudong, Ornatsky Olga, Bukhman Yury V, Ethier Martin, Sheng Yinglun, Vasilescu Julian, Abu-Farha Mohamed, Lambert Jean-Philippe, Duewel Henry S, Stewart Ian I, Kuehl Bonnie, Hogue Kelly, Colwill Karen, Gladwish Katharine, Muskat Brenda, Kinach Robert, Adams Sally-Lin, Moran Michael F, Morin Gregg B, Topaloglou Thodoros, Figeys Daniel (2007). "Large-scale mapping of human protein–protein interactions by mass spectrometry". Mol. Syst. Biol. (England) 3 (1): 89.  
  5. ^ Jeffrey, P D; Tong L; Pavletich N P (December 2000). "Structural basis of inhibition of CDK–cyclin complexes by INK4 inhibitors". Genes Dev. (UNITED STATES) 14 (24): 3115–25.  

Further reading

  • Serrano M, Hannon GJ, Beach D (1994). "A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4". Nature 366 (6456): 704–7.  
  • Ghosh PK, Anderson J, Cohen N, et al. (1993). "Expression of the leukemia-associated gene, p18, in normal and malignant tissues; inactivation of expression in a patient with cleaved B cell lymphoma/leukemia". Oncogene 8 (10): 2869–72.  
  • Simos G, Maison C, Georgatos SD (1996). "Characterization of p18, a component of the lamin B receptor complex and a new integral membrane protein of the avian erythrocyte nuclear envelope". J. Biol. Chem. 271 (21): 12617–25.  
  • Ragione FD, Russo GL, Oliva A, et al. (1996). "Biochemical characterization of p16INK4- and p18-containing complexes in human cell lines". J. Biol. Chem. 271 (27): 15942–9.  
  • Lapointe J, Lachance Y, Labrie Y, Labrie C (1996). "A p18 mutant defective in CDK6 binding in human breast cancer cells". Cancer Res. 56 (20): 4586–9.  
  • Venkataramani R, Swaminathan K, Marmorstein R (1998). "Crystal structure of the CDK4/6 inhibitory protein p18INK4c provides insights into ankyrin-like repeat structure/function and tumor-derived p16INK4 mutations". Nat. Struct. Biol. 5 (1): 74–81.  
  • Fåhraeus R, Laín S, Ball KL, Lane DP (1998). "Characterization of the cyclin-dependent kinase inhibitory domain of the INK4 family as a model for a synthetic tumour suppressor molecule". Oncogene 16 (5): 587–96.  
  • Iolascon A, Giordani L, Moretti A, et al. (1998). "Analysis of CDKN2A, CDKN2B, CDKN2C, and cyclin Ds gene status in hepatoblastoma". Hepatology 27 (4): 989–95.  
  • Noh SJ, Li Y, Xiong Y, Guan KL (1999). "Identification of functional elements of p18INK4C essential for binding and inhibition of cyclin-dependent kinase (CDK) 4 and CDK6". Cancer Res. 59 (3): 558–64.  
  • Li J, Byeon IJ, Ericson K, et al. (1999). "Tumor suppressor INK4: determination of the solution structure of p18INK4C and demonstration of the functional significance of loops in p18INK4C and p16INK4A". Biochemistry 38 (10): 2930–40.  
  • Schreiber M, Muller WJ, Singh G, Graham FL (1999). "Comparison of the effectiveness of adenovirus vectors expressing cyclin kinase inhibitors p16INK4A, p18INK4C, p19INK4D, p21(WAF1/CIP1) and p27KIP1 in inducing cell cycle arrest, apoptosis and inhibition of tumorigenicity". Oncogene 18 (9): 1663–76.  
  • Dias Neto E, Correa RG, Verjovski-Almeida S, et al. (2000). "Shotgun sequencing of the human transcriptome with ORF expressed sequence tags". Proc. Natl. Acad. Sci. U.S.A. 97 (7): 3491–6.  
  • Korshunov A, Golanov A (2002). "Immunohistochemical analysis of p18INK4C and p14ARF protein expression in 117 oligodendrogliomas: correlation with tumor grade and clinical outcome". Arch. Pathol. Lab. Med. 126 (1): 42–8.  
  • Blais A, Monté D, Pouliot F, Labrie C (2002). "Regulation of the human cyclin-dependent kinase inhibitor p18INK4c by the transcription factors E2F1 and Sp1". J. Biol. Chem. 277 (35): 31679–93.  
  • Arcellana-Panlilio MY, Egeler RM, Ujack E, et al. (2002). "Evidence of a role for the INK4 family of cyclin-dependent kinase inhibitors in ovarian granulosa cell tumors". Genes Chromosomes Cancer 35 (2): 176–81.  
  • Strausberg RL, Feingold EA, Grouse LH, et al. (2003). "Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences". Proc. Natl. Acad. Sci. U.S.A. 99 (26): 16899–903.  
  • Komata T, Kanzawa T, Takeuchi H, et al. (2004). "Antitumour effect of cyclin-dependent kinase inhibitors (p16INK4A, p18INK4C, p19INK4D, p21WAF1/CIP1 and p27KIP1) on malignant glioma cells". Br. J. Cancer 88 (8): 1277–80.  
  • Sánchez-Aguilera A, Delgado J, Camacho FI, et al. (2004). "Silencing of the p18INK4c gene by promoter hypermethylation in Reed-Sternberg cells in Hodgkin lymphomas". Blood 103 (6): 2351–7.  

External links

Cyclin
CDK
CDK inhibitor
P53 p63 p73 family
Other
Phases and
checkpoints
Interphase
M phase
Cell cycle checkpoints
Other cellular phases
  • '' : dna
    • /
  • stru


This article was sourced from Creative Commons Attribution-ShareAlike License; additional terms may apply. World Heritage Encyclopedia content is assembled from numerous content providers, Open Access Publishing, and in compliance with The Fair Access to Science and Technology Research Act (FASTR), Wikimedia Foundation, Inc., Public Library of Science, The Encyclopedia of Life, Open Book Publishers (OBP), PubMed, U.S. National Library of Medicine, National Center for Biotechnology Information, U.S. National Library of Medicine, National Institutes of Health (NIH), U.S. Department of Health & Human Services, and USA.gov, which sources content from all federal, state, local, tribal, and territorial government publication portals (.gov, .mil, .edu). Funding for USA.gov and content contributors is made possible from the U.S. Congress, E-Government Act of 2002.
 
Crowd sourced content that is contributed to World Heritage Encyclopedia is peer reviewed and edited by our editorial staff to ensure quality scholarly research articles.
 
By using this site, you agree to the Terms of Use and Privacy Policy. World Heritage Encyclopedia™ is a registered trademark of the World Public Library Association, a non-profit organization.
 


Copyright © World Library Foundation. All rights reserved. eBooks from Project Gutenberg are sponsored by the World Library Foundation,
a 501c(4) Member's Support Non-Profit Organization, and is NOT affiliated with any governmental agency or department.